Vericel Corp (VCEL) valuation
Vericel P/E ratio history
Vericel trades at 83.9 times its earnings over the last twelve months and 59.2 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $36.01 | $0.32 | 112.5 | — |
| Dec 31, 2024 | $54.91 | $0.20 | 274.6 | 136.4 |
| Dec 31, 2023 | $35.61 | -$0.07 | n/m | — |
| Dec 31, 2022 | $26.34 | -$0.35 | n/m | — |
| Dec 31, 2021 | $39.30 | -$0.16 | n/m | — |
| Dec 31, 2020 | $30.88 | $0.05 | n/m | — |
| Dec 31, 2019 | $17.40 | -$0.25 | n/m | — |
| Dec 31, 2018 | $17.40 | -$0.24 | n/m | — |
| Dec 31, 2017 | $5.45 | -$0.52 | n/m | — |
| Dec 31, 2016 | $3.00 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Vericel valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| VericelVCEL | $2.06B | 83.9 | 59.2 | 6.7 |
| ImmunomeIMNM | $2.06B | — | — | — |
| Genedx HoldingsWGS | $2.05B | — | 104.1 | 4.5 |
| Astrana HealthASTH | $2.04B | 44.6 | 10.9 | 0.5 |
| SchrodingerSDGR | $2.03B | — | — | 7.8 |
| FortreaFTRE | $2.02B | — | 19.8 | 0.8 |
| ZymeworksZYME | $2.09B | — | 24.1 | 56.3 |
| Palvella TherapeuticsPVLA | $2.10B | — | — | — |
| Maravai LifesciencesMRVI | $2.02B | — | — | 9.7 |
| Peer median | 44.6 | 21.9 | 6.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: VCEL financials · VCEL returns
No forecast, no recommendation. This page describes Vericel Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.